Free Trial

Icosavax (ICVX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
Dividend Yield
Price Target
ICVX stock logo

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

ICVX Stock News Headlines

NervGen Pharma Corp Ordinary Shares NGEN
Icosavax: Tender Offer With Contingent Value Right
Icosavax CVR Seems Fairly Valued
Guggenheim Downgrades Icosavax (ICVX)
ICVX Jul 2024 15.000 call
Icosavax just downgraded at Jefferies, here's why
Icosavax just downgraded at William Blair, here's why
Icosavax initiated with a Buy at Guggenheim
See More Headlines
Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.47 per share


Free Float
Market Cap
$766.88 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Adam K. Simpson (Age 48)
    President, CEO, Co-Founder & Director
    Comp: $855.95k
  • Mr. Niranjan Kanesa-thasan M.D. (Age 63)
    Chief Medical Officer
    Comp: $641.55k
  • Dr. Cassia Cearley Ph.D. (Age 41)
    Treasurer & Chief Business Officer
    Comp: $632.15k
  • Mr. Neil King Ph.D.
    Chair of Scientific Advisory Board & Co-Founder
  • Dr. David Baker M.D.
    Ph.D., Co-founder & Member of Scientific Advisory Board
  • Mr. Thomas Joseph Russo C.F.A. (Age 52)
    Chief Financial Officer
    Comp: $525.27k
  • Ms. Jennifer Raymond
    Senior Vice President of Technical Operations
  • Ms. Elizabeth Bekiroglu (Age 54)
    General Counsel & Corporate Secretary
    Comp: $230.74k
  • Ms. Lori Stewart
    Senior Vice President of People & Culture
  • Dr. Ami Shah Brown MPH
    Ph.D., Senior Vice President of Regulatory Affairs

ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares.
View ICVX analyst ratings
or view top-rated stocks.

What is Icosavax's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for Icosavax's shares. Their ICVX share price targets range from $25.00 to $28.00. On average, they predict the company's stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for ICVX
or view top-rated stocks among Wall Street analysts.

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to analysts' expectations of $3.30 million.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Who are Icosavax's major shareholders?

Icosavax's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include Adam K Simpson, Cassia Cearley, Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo.
View institutional ownership trends

This page (NASDAQ:ICVX) was last updated on 5/30/2024 by Staff

From Our Partners